GY
Therapeutic Areas
Bolt Biotherapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| BDC-4182 | Gastric Cancer, Gastroesophageal Junction Cancer (Claudin 18.2+) | Phase 1 |
| Macrophage-Targeting Agonist Antibody | Undisclosed Solid Tumors | Phase 1 |
| Preclinical ISAC 1 | Undisclosed | Preclinical |
| Preclinical ISAC 2 | Undisclosed | Preclinical |
Leadership Team at Bolt Biotherapeutics
WQ
Willie Quinn
Chief Executive Officer
MN
Michael N. Alonso, Ph.D.
SVP, Research
SN
Sarah Nemec
SVP, Finance and Principal Accounting Officer
BO
Brian O'Callaghan
Board Chair
LB
Laura Berner
Board Director
JD
Jakob Dupont, M.D.
Board Director
KL
Kathleen LaPorte
Board Director
NO
Nicole Onetto, M.D.
Board Director